

Quantitative Systems Pharmacology (QSP) Summit

September 15, 2022 | Le Meridien Boston Cambridge

Start Time (ET)	Event
8:45 AM	Breakfast and Registration
9:15 AM	Opening Remarks
9:30 AM	Greg Moore, PhD Director of Protein Engineering at Xencor <i>"Enabling selective activity of CD28 and TGFbR2 bispecific antibodies through cis or trans avidity engineering"</i>
10:00 AM	Abed Alnaif, PhD Principal Scientist - Translational Quantitative Pharmacology at EMD Serono <i>"Predicting the incidence proportion of drug-induced serotonin syndrome-associated tremors using a model-based meta-analysis"</i>
10:30 AM	Break and Poster Viewing Session
11:00 AM	Mark Stroh, PhD Vice President and Head, Clinical Pharmacology at Intellia Therapeutics <i>"Less may be more for TTR in ATTR: model-predicted outcomes of TTR reductions"</i>
11:30 AM	Lightning Talks <i>Three, ten-minute talks selected from abstract submissions</i> Ali Khalilimeybodi, PhD Postdoctoral Researcher at UC San Diego <i>"Signalling network model of cardiomyocyte morphological changes in familial cardiomyopathy"</i> Frank Schaefer, PhD Postdoctoral Researcher at MIT <i>"Differentiation of discontinuities in ordinary differential equations arising from dosing"</i> Monish Kumar PhD Student at University of Houston <i>"Quantitative modeling of host infection to guide design of antiviral therapeutics and vaccines"</i>
12:00 PM	Lunch and Poster Viewing Session

Start Time (ET)	Event
1:00 PM	<p>Panteleimon Mavroudis, PhD Senior Principal Scientist - Lab Head, Quantitative Pharmacology at Sanofi <i>"Model-Based Approaches to Guide Feasibility and Design of Multispecific Biotherapeutics"</i></p>
1:30 PM	<p>Leah Terrian PhD Graduate Student at Michigan State University <i>"Cell Differentiation as a Critical State Transition"</i></p>
2:00 PM	<p>Alison Betts, PhD Vice President of Scientific Collaborations and Fellow of Modeling & Simulation at Applied BioMath <i>"More than the sum of their parts: integrating data and knowledge of ADCs in a QSP platform model to predict efficacy and toxicity"</i></p>
2:30 PM	Break and Poster Viewing Session
3:00 PM	<p>Brian Schmidt, PhD Executive Director, Head QSP & PBPK at Bristol Myers Squibb <i>"Increasing the probability of success: supporting a diverse pipeline with a variety of mechanistic modeling approaches"</i></p>
3:30 PM	<p>Hiroyuki Sayama, PhD Research Fellow at Astellas Pharma <i>"A Quantitative Systems Pharmacology Approach in Oncology Drug Development - Virtual Clinical Trial Simulation for a KRASG12C inhibitor"</i></p>
4:00 PM	Break
4:15 PM	<p>QSP Summit Executive Roundtable <i>Pharma and biotech executives who think like mechanistic modelers, work with mechanistic modelers, but are not mechanistic modelers</i></p> <p>David de Graaf, PhD Strategic Advisor at Abcuro, Inc.</p> <p>Nathan Higginson-Scott, PhD Chief Technology Officer and SVP, Drug Creation at Seismic Therapeutic</p> <p>Tatiana Novobrantseva, PhD Chief Scientific Officer, Immuno-oncology Research at Moderna</p>
5:15 PM	Closing Remarks and Poster Awards
5:30 PM	QSP Summit Concludes